Document is current
Any future updates will be listed below
-
Authors
Fukui-Morimoto, Ayano
Serizawa, Kentaro
Fujimoto, Ko
Hanamoto, Aki
Iwata, Yoshio
Kakutani, Hiroaki
Kumode, Takahiro
Hirase, Chikara
Morita, Yasuyoshi
Tatsumi, Yoichi
Hanamoto, Hitoshi
Tanaka, Hirokazu
Matsumura, Itaru
- License Information
-
More Information
Article History
Received: 7 October 2024
Revised: 30 October 2024
Accepted: 30 October 2024
First Online: 12 November 2024
Declarations
:
: K.S. received personal fees from ONO PHARMACEUTICAL CO., LTD., Janssen Pharmaceutical K.K, Takeda Pharmaceutical Company Limited, Sanofi, and Bristol-Myers Squibb (Celgene). Y.M. received personal fees from AbbVie GK, NIPPON SHINYAKU CO., LTD., and Alexion Pharmaceuticals, Inc. H.H. received personal fees from Pfizer Japan Inc., CSL Behring, and Takeda Pharmaceutical Company Limited. H.T. received grants from JSPS KAKENHI, ONO PHARMACEUTICAL CO., LTD., and Kyowa Kirin Co., Ltd.; personal fees from Bristol-Myers Squibb (Celgene), Novartis Pharmaceuticals, ONO PHARMACEUTICAL CO., LTD., Janssen Pharmaceutical K.K, Takeda Pharmaceutical Company Limited., Sanofi, Meiji Seika Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Adaptive Biotechnologies. S.R. received personal fees from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Bristol-Myers Squibb (Celgene), Janssen Pharmaceutical K.K, Takeda Pharmaceutical Company Limited., and Amgen BioPharma K.K., and Mundipharma K.K. I.M. received grants from ONO PHARMACEUTICAL CO., LTD., NIPPON SHINYAKU CO., LTD., Kyowa Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Shionogi & Co., Ltd., TEIJIN PHARMA LIMITED., Boehringer Ingelheim, Sanofi, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., MSD K.K, ASAHI KASEI PHARMA CORPORATION, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited., Japan Blood Products Organization, NIHON PHARMACEUTICAL CO., LTD, DAIICHI SANKYO COMPANY, TAIHO PHARMACEUTICAL CO., LTD., Mitsubishi Tanabe Pharma Corporation, Nippon Kayaku Co.,Ltd., CSL Behring, Mundipharma K.K, AYUMI Pharmaceutical Corporation, Eli Lilly Japan K.K., and Actelion Pharmaceuticals Japan Ltd.,; personal fees from Bristol-Myers Squibb (Celgene), Novartis Pharmaceuticals, ONO PHARMACEUTICAL CO., LTD., Janssen Pharmaceutical K.K, NIPPON SHINYAKU CO.,LTD., Shionogi & Co., Ltd., Astellas Pharma Inc., Takeda Pharmaceutical Company Limited., DAIICHI SANKYO COMPANY, AbbVie GK, and Amgen BioPharma K.K. The remaining authors declare no competing financial interests. The remaining authors declare no competing financial interests.
: All samples were collected after obtaining the approval of the ethics committee of our institute (Authorization Number: 24-017, -018) and the written informed consent from the patients. This study was conducted according to the Declaration of Helsinki.
